http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104511028-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 |
| filingDate | 2013-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104511028-B |
| titleOfInvention | Application of the KLF9 genes in liver cancer is suppressed |
| abstract | The invention discloses application of the KLF9 genes in liver cancer is suppressed.In particular it relates to KLF9 (Kr ü ppel like factor9, KLF9) gene, albumen or purposes of its accelerator, for preparing p53 agonist；And/or for preparing the pharmaceutical composition for the treatment of liver cancer.In addition, present invention also offers the ZNF domains from KLF9, its active fragment as KLF9 albumen, played an important role in liver cancer is suppressed. |
| priorityDate | 2013-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 277.